Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Eyepoint Pharmaceuticals Inc (EYPT)

9.93   0.11 (1.12%) 01-16 05:25
Open: 9.94 Pre. Close: 9.82
High: 9.99 Low: 9.5
Volume: 325,746 Market Cap: 337M
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.013 - 10.08 10.08 - 10.14
Low: 9.34 - 9.422 9.422 - 9.497
Close: 9.799 - 9.933 9.933 - 10.053

Technical analysis

as of: 2022-01-15 8:46:16 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 15.05     One year: 17.50
Support: Support1: 9.50    Support2: 7.90
Resistance: Resistance1: 12.89    Resistance2: 14.98
Pivot: 12.34
Moving Average: MA(5): 11.02     MA(20): 12.63
MA(100): 12.65     MA(250): 11.08
MACD: MACD(12,26): -0.90     Signal(9): -0.59
Stochastic oscillator: %K(14,3): 4.08     %D(3): 7.60
RSI: RSI(14): 29.28
52-week: High: 21.50  Low: 7.30  Change(%): 0.4
Average Vol(K): 3-Month: 85762  10-Days: 44712

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
EYPT has closed above bottom band by 0.5%. Bollinger Bands are 60.8% wider than normal. The large width of the bands suggest high volatility as compared to EYPT's normal range. The bands have been in this wide range for 1 bars. This is a sign that the current trend might continue.

Headline News

Mon, 10 Jan 2022
EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements - Yahoo Finance

Tue, 04 Jan 2022
What You Need To Know About EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Investor Composition - Yahoo Finance

Tue, 07 Dec 2021
EyePoint Pharmaceuticals and Harrow Health's ImprimisRx - GlobeNewswire

Wed, 17 Nov 2021
Why EyePoint Pharmaceuticals Shot 31% Higher Today - The Motley Fool

Thu, 04 Nov 2021
What Kind Of Shareholders Own EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)? - Simply Wall St

Tue, 12 Oct 2021
EyePoint Pharmaceuticals Presents Preliminary Safety Data - GlobeNewswire

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M)
% Held by Insiders
% Held by Institutions
Shares Short (K)
Shares Short P. Month (K)

Stock Financials

EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.) 0.389
Sales Per Share 1.131
EBITDA (p.s.) -1.621
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

PE Ratio
PEG Ratio
Price to Book value
Price to Sales 8.78
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date 2020-12-08
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.